In the past week, CGTX stock has gone up by 18.27%, with a monthly decline of -3.90% and a quarterly plunge of -43.85%. The volatility ratio for the week is 9.18%, and the volatility levels for the last 30 days are 10.54% for Cognition Therapeutics Inc The simple moving average for the past 20 days is 16.35% for CGTX’s stock, with a -32.17% simple moving average for the past 200 days.
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
The 36-month beta value for CGTX is at 1.00. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGTX is 50.22M, and currently, shorts hold a 3.07% of that float. The average trading volume for CGTX on April 25, 2025 was 1.37M shares.
CGTX) stock’s latest price update
Cognition Therapeutics Inc (NASDAQ: CGTX)’s stock price has plunge by 15.25relation to previous closing price of 0.38. Nevertheless, the company has seen a 18.27% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-01 that Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population
Analysts’ Opinion of CGTX
Many brokerage firms have already submitted their reports for CGTX stocks, with B. Riley Securities repeating the rating for CGTX by listing it as a “Buy.” The predicted price for CGTX in the upcoming period, according to B. Riley Securities is $1.50 based on the research report published on December 19, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to CGTX, setting the target price at $22 in the report published on November 03rd of the previous year.
CGTX Trading at -0.37% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.04% of loss for the given period.
Volatility was left at 10.54%, however, over the last 30 days, the volatility rate increased by 9.18%, as shares sank -0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.46% lower at present.
During the last 5 trading sessions, CGTX rose by +18.27%, which changed the moving average for the period of 200-days by -76.52% in comparison to the 20-day moving average, which settled at $0.3794. In addition, Cognition Therapeutics Inc saw -37.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 38,851 shares at the price of $0.77 back on Jan 31 ’25. After this action, Ricciardi Lisa now owns 38,851 shares of Cognition Therapeutics Inc, valued at $30,001 using the latest closing price.
Stock Fundamentals for CGTX
The total capital return value is set at -2.83. Equity return is now at value -157.19, with -103.89 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -34.98. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -2158.64.
Currently, EBITDA for the company is -53.97 million with net debt to EBITDA at 0.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.
Conclusion
In conclusion, Cognition Therapeutics Inc (CGTX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
